Filtered By:
Specialty: Drugs & Pharmacology
Cancer: Breast Cancer

This page shows you your search results in order of date. This is page number 8.

Order by Relevance | Date

Total 139 results found since Jan 2013.

BACH1 silencing by siRNA inhibits migration of HT-29 colon cancer cells through reduction of metastasis-related genes
Conclusion Our results indicated that BACH1 down-regulation in HT29 CRC cells had no effect on cell growth but did inhibit cell migration by decreasing metastasis-related genes expression. Collectively, these results suggest that BACH1 may function as an oncogenic driver in colon cancer and may represent as a potential target of gene therapy for CRC treatment.
Source: Biomedicine and Pharmacotherapy - September 19, 2016 Category: Drugs & Pharmacology Source Type: research

BACH1 silencing by siRNA inhibits migration of HT-29 colon cancer cells through reduction of metastasis-related genes.
CONCLUSION: Our results indicated that BACH1 down-regulation in HT29 CRC cells had no effect on cell growth but did inhibit cell migration by decreasing metastasis-related genes expression. Collectively, these results suggest that BACH1 may function as an oncogenic driver in colon cancer and may represent as a potential target of gene therapy for CRC treatment. PMID: 27657827 [PubMed - as supplied by publisher]
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - September 18, 2016 Category: Drugs & Pharmacology Authors: Davudian S, Shajari N, Kazemi T, Mansoori B, Salehi S, Mohammadi A, Shanehbandi D, Shahgoli VK, Asadi M, Baradaran B Tags: Biomed Pharmacother Source Type: research

Reversal of multidrug resistance in breast cancer MCF-7/ADR cells by h-R3-siMDR1-PAMAM complexes
In this study, anti-EGFR antibody h-R3 was designed to self-assembled h-R3-siRNA-PAMAM-complexes (HSPCs) via electrostatic interactions for siRNA delivery. The physicochemical characterization, cell uptake, MDR1 silencing efficiency, cell migration, cell growth and cell apoptosis were investigated. The HSPCs presented lower cytotoxicity, higher cellular uptake and enhanced endosomal escape ability. Also, HSPCs encapsulating siMDR1 knockdowned 99.4% MDR1 gene with up to ∼6 times of enhancement compared to naked siMDR1, increased the doxorubicin accumulation, down-regulated P-glycoprotein (P-gp) expression and suppressed c...
Source: International Journal of Pharmaceutics - July 25, 2016 Category: Drugs & Pharmacology Source Type: research

Vitamin E promotes breast cancer cell proliferation by reducing ROS production and p53 expression.
CONCLUSIONS: Vitamin E accelerated breast cancer growth by reducing ROS production and p53 expression. PMID: 27383327 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - July 9, 2016 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research

MHP-1 inhibits cancer metastasis and restores topotecan sensitivity via regulating epithelial-mesenchymal transition and TGF-β signaling in human breast cancer cells
Conclusion MHP-1 significantly inhibited breast cancer metastasis and restored drug sensitivity in TPT-resistant cells via down-regulation of TGF-β signaling and EMT program. The combination of non-toxic agents like MHP-1 and current anti-cancer drugs should be considered in the future treatment of cancer. Graphical abstract
Source: Phytomedicine - July 4, 2016 Category: Drugs & Pharmacology Source Type: research

Co-delivery of IL17RB siRNA and doxorubicin by chitosan-based nanoparticles for enhanced anticancer efficacy in breast cancer cells
In conclusion, co-delivery of IL17RB siRNA and DOX can be considered as an effective system for the treatment of breast cancer.
Source: Biomedicine and Pharmacotherapy - June 30, 2016 Category: Drugs & Pharmacology Source Type: research

MiR-99a suppress proliferation, migration and invasion through regulating insulin-like growth factor 1 receptor in breast cancer.
CONCLUSIONS: Our findings demonstrated that miR-99a could inhibit the malignancy of breast cancer cell by directly down-regulation of IGF-1R. These results indicated that miR-99a may be an important biomarker for prognosis and anticancer therapy in breast cancer in the future. PMID: 27212167 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - May 25, 2016 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research

Psoralidin induced reactive oxygen species (ROS)-dependent DNA damage and protective autophagy mediated by NOX4 in breast cancer cells
Conclusions Taken together, these results showed that PSO induced DNA damage and protective autophagy mediated by ROS generation in a NOX4-dependent manner in MCF-7 cells. Graphical abstract
Source: Phytomedicine - May 24, 2016 Category: Drugs & Pharmacology Source Type: research

USP4 promotes invasion of breast cancer cells via Relaxin/TGF-β1/Smad2/MMP-9 signal.
CONCLUSIONS: Therapies targeting the USP4 inhibits invasion of breast cancer cells via Relaxin/TGF-β1/Smad2/MMP-9 signal. These results indicate that USP4 is an attractive target for breast cancer therapy. PMID: 27049265 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - April 8, 2016 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research

Aryl hydrocarbon receptor (AHR) regulation of L-Type Amino Acid Transporter 1 (LAT-1) expression in MCF-7 and MDA-MB-231 breast cancer cells.
Abstract The aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor that is regulated by environmental toxicants that function as AHR agonists such as 2,3,7,8 tetrachlorodibenzo-p-dioxin (TCDD). L-Type Amino Acid Transporter 1 (LAT1) is a leucine transporter that is overexpressed in cancer. The regulation of LAT1 by AHR in MCF-7 and MDA-MB-231 breast cancer cells (BCCs) was investigated in this report. Ingenuity pathway analysis (IPA) revealed a significant association between TCDD-regulated genes (TRGs) and molecular transport. Overlapping the TCDD-RNA-Seq dataset obtained in this study with a...
Source: Biochemical Pharmacology - March 1, 2016 Category: Drugs & Pharmacology Authors: Tomblin JK, Arthur S, Primerano DA, Chaudhry AR, Fan J, Denvir J, Salisbury TB Tags: Biochem Pharmacol Source Type: research

Retinoid N-(1H-benzodimidazol-2-yl)-5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalene-2-carboxamide induces p21-dependent senescence in breast cancer cells
Publication date: Available online 17 February 2016 Source:Steroids Author(s): Mine Mumcuoglu, A. Selen Gurkan-Alp, Erdem Buyukbingol, Rengul Cetin-Atalay Retinoids have been implicated as pharmacological agents for the prevention and treatment of various types of cancers, including breast cancers. We analysed 27 newly synthesized retinoids for their bioactivity on breast, liver, and colon cancer cells. Majority of the retinoids demonstrated selective bioactivity on breast cancer cells. Retinoid 17 had a significant inhibitory activity (IC50 3.5 μM) only on breast cancer cells while no growth inhibition observed wit...
Source: Steroids - February 19, 2016 Category: Drugs & Pharmacology Source Type: research

Clinical significance of sCIP2A levels in breast cancer.
CONCLUSIONS: Our results suggest that serum CIP2A is significantly higher in patients with breast cancer, which is a potential biomarker to make a distinction between breast cancer patients and healthy controls. Higher serum CIP2A levels positively associated with the aggressive phenotype of breast cancer, and forecasts poor prognosis for patients with breast cancer. Knockdown of CIP2A may be a novel target for prevention and treatment of breast cancer. PMID: 26813457 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - January 29, 2016 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research

Overcoming Akt Induced Therapeutic Resistance in Breast Cancer through siRNA and Thymoquinone Encapsulated Multilamellar Gold Niosomes
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.5b00692
Source: Molecular Pharmaceutics - November 10, 2015 Category: Drugs & Pharmacology Authors: Shashi Rajput, Nagaprasad Puvvada, B. N. Prashanth Kumar, Siddik Sarkar, Suraj Konar, Rashmi Bharti, Goutam Dey, Abhijit Mazumdar, Amita Pathak, Paul B. Fisher and Mahitosh Mandal Source Type: research

Inhibition of murine breast cancer growth and metastasis by survivin-targeted siRNA using disulfide cross-linked linear PEI.
In this study, we developed and characterized a hyperbranched disulfide cross-linked PEI (lPEI-SS) based on linear PEI (lPEI) by ring-opening reaction of propylene sulfide. We evaluated the efficiency of lPEI-SS as a siRNA vector in vitro with luciferase reporter gene system, and investigated the anti-tumor efficacy of survivin-targeted siRNA (siRNA(sur)) on 4T1 murine breast cancer model using lPEI-SS synthesized here. Results from cytotoxicity and hemolysis assay proved that lPEI-SS showed favorable cell and blood compatibility. lPEI-SS/siRNA polyplexes prepared under the optimized condition were compact spherical partic...
Source: European Journal of Pharmaceutical Sciences - November 7, 2015 Category: Drugs & Pharmacology Authors: Liu S, Huang W, Jin MJ, Fan B, Xia GM, Gao ZG Tags: Eur J Pharm Sci Source Type: research

Piroxicam, a traditional non-steroidal anti-inflammatory drug (NSAID) causes apoptosis by ROS mediated Akt activation.
DISCUSSION: Our studies with human breast cancer cells MCF-7 show that Px induces reactive oxygen species (ROS) generation along with apoptotic cell death. ROS release lead to Akt activation. On evaluation it became evident that ROS mediated apoptosis induction was due to Akt activation (hyper phosphorylation). Silencing the expression of Akt using siRNA and a specific Akt inhibitor, triciribine further confirmed the findings. However Px failed to cause ROS generation, cell death or Akt phosphorylation in another human breast cancer cells MDA-MB-231 which is estrogen receptor negative and more aggressive compared to MCF-7 ...
Source: Pharmacological Reports - October 24, 2015 Category: Drugs & Pharmacology Authors: Rai N, Sarkar M, Raha S Tags: Pharmacol Rep Source Type: research